Dr. David Fajgenbaum, physician-scientist, best-selling author of Chasing My Cure, and Co-Founder of Every Cure, shares his journey from a patient given last rites five times to a leader reshaping how rare diseases are treated. By turning personal adversity into scientific discovery, he pioneered a path to curing his own Castleman disease and now leads efforts to unlock treatments for overlooked conditions. In this keynote, Dr. Fajgenbaum challenges Medical Affairs professionals to adopt the same relentless mindset: executing a mission to drive meaningful change for patients.

This session explores how Medical Affairs teams navigate high-stakes crises from drug safety events and misinformation outbreaks to organizational restructures and operational disruption. Panelists will share real-world examples of managing both external and internal reputational threats while preserving scientific credibility, patient trust, and regulatory alignment. Attendees will gain actionable frameworks to proactively prepare their teams, communicate with transparency, and recover stronger

Is your medical affairs team speaking the language of executives? This panel discussion brings leaders who have successfully championed Medical Affairs at the enterprise level to discuss how strategy is shaped, funded, and defended within the C-suite. Gain an inside look into how Medical Affairs is viewed from leadership and how to build alignment and credibility at the highest level.

Physicians are not overwhelmed by access. They are overwhelmed by irrelevance. As clinical complexity increases and digital noise grows, doctors are becoming far more selective about when, how, and with whom they engage from industry.

This session shows how Medical Affairs leaders can shift from broad outreach to precision engagement through right channeling. Using physician preference data, real-world behavior, and AI-powered decisioning, teams can predict when physicians want to self-serve medical content and when they are ready for a meaningful interaction with an MSL or other medical partner.

Recognizing exceptional contributions to innovation, leadership, and impact in medical affairs.

Shifting policies, payer pressures, and geopolitical shifts continue to redefine evidence expectations, communication standards, and field engagement rules. This session unpacks the latest regulatory and political forces shaping Medical Affairs strategy.

With the volume of scientific data accelerating, traditional education models can no longer keep pace with evolving HCP needs. A persistent “evidence‑to‑practice” lag limits patient impact. This session introduces agentic AI, multi-agent systems (MAS) and systems of agent networks (SAN) that streamline evidence assessment, content creation, and omnichannel delivery to close that lag between discovery and clinical adoption. Through a demo of Cognizant’s NeuroSAN, attendees will see how AI-driven tools can personalize HCP learning needs while adhering to standards of medical affairs (ACMA, IACET, ANSI, ACCME, ACPE)

Can Medical Affairs be used as an economic signal? Engage with a leading healthcare equity analyst that will break down how institutional investors and Wall Street evaluate pharmaceutical/biotech companies and their Medical Affairs indicators, to predict performance